<DOC>
	<DOCNO>NCT02113501</DOCNO>
	<brief_summary>Non-muscle invasive bladder cancer High Grade stage T1 ( HGT1 ) , 20 % risk progression invasive disease . Because depth substaging seem identify two separate group different progression risk ( HighGradeT1a HighGradeT1b ) , design differential treatment strategy group . The main hypothesis HighGradeT1a bladder cancer spare second endoscopic procedure .</brief_summary>
	<brief_title>Optimized Treatment Strategy HighGrade1 ( HGT1 ) Bladder Cancer Based Substaging : Prospective Observational Cohort Study</brief_title>
	<detailed_description>Only case initial diagnosis HighGradeT1 complete transurethral endoscopic resection ( TUR ) bladder tumor ) enter protocol . HighGradeT1a receive standard BCG treatment ( induction maintenance ) . HighGradeT1b undergo second transurethral endoscopic resection ( TUR ) induction Bacillus de Calmette-Guerin ( BCG ) continue mantenaince BCG standard follow-up .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>HGT1 bladder cancer initial diagnosis complete TUR abscence muscularis propria TUR specimen</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>HGT1</keyword>
	<keyword>high risk bladder cancer</keyword>
	<keyword>substaging</keyword>
	<keyword>repeat transurethral resection ( reTUR )</keyword>
	<keyword>lamina propria</keyword>
</DOC>